A top US-based life sciences consulting firm sought Regulatory assistance from Freyr for filing Investigational New Drug (IND) submissions and amendments with the USFDA.
Freyr successfully completed the end-to-end publishing activities for the project within a tight timeline. With granular document-level publishing (DLP) services, the IND submissions and document amendments were made on time without any errors or warnings from the USFDA.
Discover how Freyr provided comprehensive Regulatory services and made high-quality submissions on schedule using Agency-recommended tools. Download the case study for more details.
Fill the form below to download the Case Study
